New neuroimaging marker may identify persons at risk of dementia in future clinical trials

A new neuroimaging marker of cerebral small vessel disease is related to general cognition and may serve to identify persons at risk of dementia in future clinical trials, a landmark study has found.

J&J and Legend’s Carvykti scores early line approval for MM by FDA

Share this article J&J and Legend Biotech’s Carvykti is a B-cell maturation antigen (BCMA) directed CAR-T cell therapy. Image Credit: Corona Borealis Studio / Shutterstock.

April 8, 2024

FDA lifts hold on PepGen’s myotonic dystrophy drug; Takeda teams with cancer nonprofit

Plus, Scholar Rock’s entry into the weight loss space, new funding for Synerkine Pharma and its lead pain program, BioLineRx’s Asia deal, Hansa Biopharma’s Phase

October 13, 2023

MAPS Launches Online Video Sessions from Psychedelic Science 2023 with The Virtual Trip | Psychedelic Invest

PS2023: The Virtual Trip offers an opportunity to access a wide spectrum of sessions from Psychedelic Science 2023, the largest psychedelics conference in history. With

August 31, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.